Taro Pharmaceuticals Inc. on Tuesday recalled batches of zoledronic acid injection, a drug used to treat bone diseases such as osteoporosis or Paget’s disease due to the possible presence of specific materials that can cause blood clots in particular.
The recall affects all lots of zoledronic acid injection (Taro) 5 mg/100 mL (DIN 02415100), with references JKX1910A, JKX4318A, JKX5541A, HAC2371A, HAC4421A and HAD0156A.
Injecting specific materials can cause a risk of injury, such as inflammation or irritation of the veins, infection at the injection site or in other parts of the body, an allergic reaction and the formation of blood clots which may move to other parts of the body. In the most severe cases, blood clots can travel to the lungs and cause permanent or fatal lung damage.
Health Canada recommends people using this product check their lots and return it if affected by the recall.
If you have used the recalled product and have health concerns, contact your healthcare provider.